Aytu Biopharma (AYTU) Total Debt Growth (1y) (2012 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Total Debt Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | -2.50% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -4.39% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 52.27% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | 15.32% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.26% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 8.51% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | -17.14% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | - |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | 2.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.03% |
| Dec 31, 2025 | 5.92% |
| Sep 30, 2025 | 33.47% |
| Jun 30, 2025 | 27.39% |
| Mar 31, 2025 | 6.34% |
| Dec 31, 2024 | 5.74% |
| Sep 30, 2024 | 8.84% |
| Jun 30, 2024 | -12.18% |
| Mar 31, 2024 | -48.62% |
| Dec 31, 2023 | -42.96% |
| Sep 30, 2023 | -24.50% |
| Jun 30, 2023 | -18.56% |
| Mar 31, 2023 | 94.76% |
| Dec 31, 2022 | 81.27% |
| Sep 30, 2022 | 38.56% |
| Jun 30, 2022 | 30.02% |
| Mar 31, 2022 | 13.49% |
| Dec 31, 2021 | 20.30% |
| Sep 30, 2021 | 29.98% |
| Jun 30, 2021 | 757.81% |